Home
About Us
Membership
Member Biography

Member Biography

Nabil Adra, MD

Nabil Adra, M.D.

Phone: (317) 278-7728
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT 473
Indianapolis, IN 46202

Faculty appointments

Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate Professor of Clinical Urology, Department of Urology, IU School of Medicine
Full member, Experimental and Developmental Therapeutics

Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015IUSCC-0579

Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University IUSCC-0611

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)C16-174

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)EA8143

A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell CarcinomaIUSCC-0551

COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAMIUSCC-0584

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.S1605

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 TrialEA8153

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the Bladder (ADAPT)GU16-243

A Retrospective Tissue Analysis of NQO1 Status in Patients with Germ Cell Tumors IUSCC-0688

CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate CancerE3805

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate CancerCTO-20180146

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04ACTO-MK-3475-04A

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder CancerCTO-MK-3475-B15

PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXELNRG-GU002

MicroRNA testing in patients with testicular cancerIUSCC-0712

Genomic Analysis of Relapsed/Refractory Germ-Cell TumorsIUSCC-0708

Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients with Rising PSA at High-Risk of Progression after Primary TherapyE2809

A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) CTO-MK-3475-905

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)CTO-MK-3475-866

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III StudyS0931

A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORSCTO-S1823

Retrospective Analysis of Patients with Renal Cell Carcinoma at Indiana University: 1990-2021CTO-IUSCCC-0785

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)CTO-CAAA617C12301

A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid TumorsCTO-PT112-101

A phase II trial of sitravatinib plus nivolumab in patients with metastatic clear cell renal cell carcinoma who progressed on prior treatment Acronym: SNAPI (Sitravatinib and Nivolumab After Prior Immunotherapy)CTO-SNAPI2021-0057

Circulating Tumor DNA in Early Stage and Metastatic Non-Seminomatous Germ Cell Testicular CancerCTO-IUSCCC-0789

Sequelae of Treatment in Survivors of Testicular Cancer Creation of a Non-exposed Comparison Group for the Platinum Study IUSCC-0587

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell TumorCTO-IUSCCC-0742

A PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH ENTINOSTAT AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMAIUSCC-0574

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 as Monotherapy and in Combination Regimens, with Randomized Comparison to Investigator’s Choice of Treatment, in Subjects with Metastatic Castrationresistant Prostate Cancer who are Resistant or Refractory to Prior Standard TherapiesCTO-ARX517-2011

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) TherapyCTO-MK-3475-057

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) in Combination With Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04CCTO-MK-3475-04C

A Multinational, Multicenter, Prospective, Open-Label, Dosimetry and Safety Study of Lutetium (177Lu) rosopatamab tetraxetan in Combination with Standard of Care in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer after Androgen Receptor Pathway Inhibitor TreatmentCTO-177LU-TLX591-203

Expression of Nectin-4 in germ-cell tumors IUSCCC-0833

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)CTO-D9723C00001

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04BCTO-MK-3475-04B

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy20230005

Headlines & highlights

#ResearchCuresCancer

Support Our Research